Evidence map›Paper›PMID 40979068›Full record

ArticleBlood neoplasia2025

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Ritul Sharma, Chunfen Zhang, Ravi Shah, Melanie M Frigault, Amy J Johnson, David Spencer Mangum, Luke D Maese, Norman J Lacayo, Aru Narendran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ritul SharmaDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Chunfen ZhangDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Ravi ShahDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Melanie M FrigaultVincerx Pharma, Inc, Palo Alto, CA.
Amy J JohnsonVincerx Pharma, Inc, Palo Alto, CA.
David Spencer MangumDivision of Hematology/Oncology, Department of Pediatrics, The University of Utah and Primary Children's Hospital, Salt Lake City, UT.
Luke D MaeseDivision of Hematology/Oncology, Department of Pediatrics, The University of Utah and Primary Children's Hospital, Salt Lake City, UT.
Norman J LacayoDivision of Pediatric Hematology-Oncology, Stem Cell Transplant, and Regenerative Medicine at Lucile Packard Children's Hospital and Stanford Cancer Institute, Palo Alto, CA.
Aru NarendranDepartment of Oncology, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The KMT2A-rearranged (KMT2A-r) leukemia is one of the most challenging cancers to treat in children, owing to the higher relapse rates and chemoresistance frequently observed in this patient population. At the molecular level, chromosomal translocation in the

Identifiers

PMID40979068
PMCPMC12447890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.